Sugi Predict

Sugi Predict / Compounds / SCHEMBL859758

SCHEMBL859758

SCHEMBL859758

CCOC(=O)c1scnc1CC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.42
▸ GAA P10253 3/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ LMNA P02545 3/20 0.42
▸ KDM4E B2RXH2 5/20 0.42
▸ PKM P14618 2/20 0.42
▸ ALDH1A1 P00352 4/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ RAB9A P51151 4/20 0.41
▸ HPGD P15428 3/20 0.41
▸ NPC1 O15118 3/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ CDC7 O00311 4/20 0.40
▸ DBF4 Q9UBU7 4/20 0.40
▸ CASP1 P29466 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19940202 0.90 HSD17B10 (0.46) HSD17B10GAAKMT2ALMNAKDM4E
SCHEMBL25767003 0.87 ALDH1A1 (0.42) HSD17B10GAAKMT2ALMNAKDM4E
SCHEMBL7613832 0.87 HSP90AA1 (0.48) HSD17B10GAAKMT2ALMNAKDM4E
SCHEMBL21518879 0.87 HSD17B10 (0.43) HSD17B10GAAKMT2ALMNAKDM4E
SCHEMBL2717847 0.85 SMN1; SMN2 (0.43) HSD17B10GAAKMT2ALMNAKDM4E
SCHEMBL5528025 0.84 KMT2A (0.46) HSD17B10KMT2ALMNAKDM4EPKM
SCHEMBL31575 0.82 KDM4E (0.58) HSD17B10GAAKMT2ALMNAKDM4E
SCHEMBL3333926 0.81 ALDH1A1 (0.50) HSD17B10GAAKMT2ALMNAKDM4E
SCHEMBL29706037 0.81 CDC7 (0.47) HSD17B10GAAKMT2AKDM4EPKM
SCHEMBL2555611 0.81 ALDH1A1 (0.41) HSD17B10GAAKMT2ALMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528781-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-01-20 — — US disclosed
EP-4192831-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 — — EP disclosed
US-20240376061-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2024-11-14 — — US disclosed
US-11897851-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2024-02-13 — — US disclosed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 — — US disclosed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 — — US disclosed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 — — US disclosed
CN-116323599-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-06-23 — — CN disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 — — US disclosed
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-22 — — US disclosed
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITé LAVAL (CA) 2015-08-13 — — US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 — — US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 — — US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 — — US disclosed
EP-2432776-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS Chlorion Pharma, Inc. (CA) 2012-03-28 — — EP disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 — — US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 — — US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 — — US disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 — — WO disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP HSD17B10 2062/4885GAA 1107/4885KMT2A 3590/4885
US-20230192633-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR HSD17B10 1435/4885GAA 1010/4885KMT2A 4112/4885
US-11897851-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, GCGR HSD17B10 1435/4885GAA 1010/4885KMT2A 4112/4885
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CDC7, CDK7, CDK17 HSD17B10 1733/4885GAA 1313/4885KMT2A 2341/4885
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP HSD17B10 2062/4885GAA 1107/4885KMT2A 3590/4885
US-12528781-B2 Heterocyclic GLP-1 agonists GLP1R, GIPR, VIP HSD17B10 2210/4885GAA 1396/4885KMT2A 3022/4885
US-20240376061-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR HSD17B10 1435/4885GAA 1010/4885KMT2A 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.